US2012040891A1PendingUtilityA1
Hiv fusion inhibitor peptides with improved biological properties
Est. expiryFeb 2, 2026(expired)· nominal 20-yr term from priority
Inventors:John J. DwyerBrian BrayStephen E. SchneiderHuyi ZhangNicolai TvermoesBarbara E. JohnstonPaul E. Friedrich
A61P 31/18C07K 14/005G01N 2333/16G01N 2800/26A61K 38/00C12N 2740/16022A61P 43/00C12N 2740/16122
43
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated peptide comprising an amino acid sequence consisting of any one of the following: SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15.
2 . The peptide of claim 1 , further comprising a component selected from the group consisting of one or more reactive functionalities, a pharmaceutically acceptable carrier, a macromolecular carrier, and a combination thereof.
3 . The peptide of claim 1 , wherein the peptide is up to 60 amino acids in length.
4 . An isolated nucleic acid molecule comprising a nucleotide sequence encoding a peptide according to claim 1 .
5 . A vector comprising the nucleic acid molecule of claim 4 .
6 . The vector of claim 5 , wherein the vector is an expression vector.
7 . An isolated cell comprising the vector of claim 5 or 6 .
8 . A composition comprising the peptide of claim 2 .
9 . The composition of claim 2 , wherein the composition is sterile.
10 . A therapeutic regimen comprising a combination of antiviral agents for treatment of HIV-1, the combination comprising the peptide of claim 1 and one of more antiviral agents selected from the group consisting of an HIV entry inhibitor, HIV integrase inhibitor, reverse transcriptase inhibitor, protease inhibitor, vif-inhibitor, viral-specific transcription inhibitor, viral processing inhibitor, HIV maturation inhibitor, and a combination thereof.
11 . A method of inhibition of transmission of HIV to a cell, comprising contacting the virus, in the presence of a cell, with an amount of the peptide of claim 1 effective to inhibit infection of the cell by HIV.
12 . A method for inhibiting HIV fusion, comprising contacting the virus, in the presence of a cell, with an amount of the peptide of claim 1 effective to inhibit HIV fusion.
13 . A method for treating an HIV-infected individual, comprising administering to the individual an amount of the peptide of claim 1 effective to achieve, in the treated individual, a therapeutic result selected from the group consisting of a reduction in the HIV viral load, an increase in circulating CD4 ± cell population, and a combination thereof.
14 . A method of synthesizing the peptide of SEQ ID NO:9, wherein a set of three peptide fragments are produced by solid and solution phase synthesis, the set comprising:
(a) SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, and a leucine residue; or (b) SEQ ID NO:17, SEQ ID NO:18 and SEQ ID NO:20;
wherein the members of the set are then combined using a fragment condensation approach to produce the SEQ ID NO:9 peptide.
15 . A set of peptides, wherein the set comprises:
(a)
TTWEAWDRAIAE,
(SEQ ID NO: 17)
YAARIEALLRALQE,
(SEQ ID NO: 18)
QQEKNEAALRE;
(SEQ ID NO: 19)
(b)
TTWEAWDRAIAE,
(SEQ ID NO: 17)
YAARIEALLRALQE,
(SEQ ID NO: 18)
QQEKNEAALREL;
(SEQ ID NO: 20)
(c)
TTWEAWDRAIAEYAARIEAL,
(SEQ ID NO: 29)
LRALQEQQEKNEAALRE;
(SEQ ID NO: 30)
(d)
TTWEAWDRAIAEYAARIEAL,
(SEQ ID NO: 29)
LRALQEQQEKNEAALREL;
(SEQ ID NO: 31)
(e)
TTWEAWDRAIA,
(SEQ ID NO: 21)
EYAARIEALLRALQE,
(SEQ ID NO: 22)
QQEKNEAALRE;
(SEQ ID NO: 19)
(f)
TTWEAWDRAI,
(SEQ ID NO: 23)
AEYAARIEALLRALQE,
(SEQ ID NO: 24)
QQEKNEAALRE;
(SEQ ID NO: 19)
(g)
TTWEAWDRA,
(SEQ ID NO: 25)
IAEYAARIEALLRALQE,
(SEQ ID NO: 26)
QQEKNEAALRE;
(SEQ ID NO:19)
(h)
TTWEAWDR,
(SEQ ID NO: 27)
AIAEYAARIEALLRALQE,
(SEQ ID NO: 28)
QQEKNEAALRE;
(SEQ ID NO: 19)
(i)
TTWEAWDRAIA,
(SEQ ID NO: 21)
EYAARIEALLRALQE,
(SEQ ID NO: 22)
QQEKNEAALREL;
(SEQ ID NO: 20)
(j)
TTWEAWDRAI,
(SEQ ID NO: 23)
AEYAARIEALLRALQE,
(SEQ ID NO: 24)
QQEKNEAALREL;
(SEQ ID NO: 20)
(k)
TTWEAWDRA,
(SEQ ID NO: 25)
IAEYAARIEALLRALQE,
(SEQ ID NO: 26)
QQEKNEAALREL;
(SEQ ID NO: 20)
(l)
TTWEAWDR,
(SEQ ID NO: 27)
AIAEYAARIEALLRALQE,
(SEQ ID NO: 28)
QQEKNEAALREL;
(SEQ ID NO: 20)
(m)
TTWEAWDRAIAEYAARIE,
(SEQ ID NO: 32)
ALLRALQEQQEKNEAALRE;
(SEQ ID NO: 33)
(n)
TTWEAWDRAIAEYAARIE,
(SEQ ID NO: 32)
ALLRALQEQQEKNEAALREL;
(SEQ ID NO: 34)
(o)
TTWEAWDRAIAEYAARIEALLRALQE,
(SEQ ID NO: 40)
QQEKNEAALRE;
(SEQ ID NO: 19)
or
(p)
TTWEAWDRAIAEYAARIEALLRALQE,
(SEQ ID NO: 40),
QQEKNEAALREL.
(SEQ ID NO: 20)
16 . The set of peptides of claim 15 , wherein one or more side chains of at least one peptide is protected with a protecting group.
17 . The set of peptides of claim 16 , wherein the protecting group is selected from the group consisting of 9-fluoroenylmethoxy-carbonyl (Fmoc), t-butyl (t-Bu), trityl (trt), t-butyloxycarbonyl (Boc), carbobenzoxyl, dansyl and a para-nitrobenzyl ester group.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.